Introduction: Chronic migraine limits the quality of life of patients. This condition requires rescue and prophylactic treatment. Many patients do not respond to first-line prophylactic treatment. Since 2015, botulinum toxin A has been used in Panama for patients who do not respond to first-line prophylactic therapy.
Objective: Determine the impact of Botulinum Toxin A as a prophylactic therapy in patients with chronic migraine in Panama.
Methodology: A retrospective, descriptive study. Sample was equal to universe: 29 participants in the PREEMPT 1 protocol. Data collection was based on reviewing medical records. The study evaluated demographic and clinical characteristics, including MIDAS and HIT-6 scales scores.
Results: Participants had an average age of 43 years; all were female. A total of 55.1% experienced 25 to 30 days of acute migraine crises per month. Therapy shows a crisis reduction of 89.66% and 93.10% at 3 and 6 months, respectively. No adverse effects were reported.
Conclusions: Panamanian patients with a diagnosis of chronic migraine resistant to first-line prophylactic therapy have responded positively to treatment with botulinum toxin A, with a significant improvement in their quality of life.
